as 10-22-2025 3:52pm EST
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Founded: | 2010 | Country: | United States |
Employees: | N/A | City: | NOVATO |
Market Cap: | 3.1B | IPO Year: | 2014 |
Target Price: | $87.69 | AVG Volume (30 days): | 1.5M |
Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -5.52 | EPS Growth: | N/A |
52 Week Low/High: | $25.81 - $56.38 | Next Earning Date: | 11-03-2025 |
Revenue: | $610,159,000 | Revenue Growth: | 26.77% |
Revenue Growth (this year): | 19.72% | Revenue Growth (next year): | 23.29% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Horn Howard | RARE | Chief Financial Officer | Oct 13 '25 | Sell | $31.51 | 7,942 | $250,252.42 | 98,227 | |
Parschauer Karah Herdman | RARE | EVP and Chief Legal Officer | Sep 12 '25 | Sell | $31.17 | 2,450 | $76,366.50 | 73,271 | |
Huizenga Theodore Alan | RARE | SVP, Chief Accounting Officer | Sep 5 '25 | Sell | $31.39 | 84 | $2,636.76 | 50,306 |
RARE Breaking Stock News: Dive into RARE Ticker-Specific Updates for Smart Investing
Zacks
5 days ago
GlobeNewswire
19 days ago
Simply Wall St.
19 days ago
Simply Wall St.
20 days ago
Insider Monkey
20 days ago
MT Newswires
22 days ago
GlobeNewswire
22 days ago
Zacks
a month ago
The information presented on this page, "RARE Ultragenyx Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.